With anti-CD38 in multiple myeloma, a survival benefit too long to be significant?

被引：0
|
作者：
Cazabat, Romain
机构：
来源：
HEMATOLOGIE | 2024年 / 30卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：10
相关论文
共 50 条
  • [21] EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
    Chemlal, Djamila
    Varlet, Emmanuel
    Machura, Amelie
    Ovejero, Sara
    Requirand, Guilhem
    Robert, Nicolas
    Cartron, Guillaume
    Alaterre, Elina
    Bret, Caroline
    Vincent, Laure
    Herbaux, Charles
    Cavalli, Giacomo
    Bruyer, Angelique
    De Boussac, Hugues
    Moreaux, Jerome
    LEUKEMIA, 2023, 37 (9) : 1925 - 1928
  • [22] Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
    Zannetti, Beatrice Anna
    Faini, Angelo Corso
    Massari, Evita
    Geuna, Massimo
    Maffini, Enrico
    Poletti, Giovanni
    Cerchione, Claudio
    Martinelli, Giovanni
    Malavasi, Fabio
    Lanza, Francesco
    CELLS, 2020, 9 (12) : 1 - 13
  • [23] Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma
    Rabut, Elodie
    Castro-Fernandez, Annabelle
    Le Gall, Virginie
    Meknache, Nihad
    ANNALES DE BIOLOGIE CLINIQUE, 2017, 75 (03) : 351 - 355
  • [24] Clinical outcomes of Multiple Myeloma patients after anti-CD38 monoclonal antibodies failure
    Zamanillo, Irene
    De la Puerta, Rosalia
    Gil, Rodrigo
    Poza, Maria
    De la Puerta, Rodrigo
    Alonso, Rafael
    Cedena, Teresa
    Calbacho, Maria
    Ayala, Rosa
    Martinez-Lopez, Joaquin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S164 - S165
  • [25] Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab
    Thirkettle, Sally
    Russell, Joanne
    Wilson, Sarah
    Ganijee, Tasneem
    Kulkarni, Samar
    Cavet, Jim
    Monaghan, Phillip J.
    ANNALS OF CLINICAL BIOCHEMISTRY, 2020, 57 (02) : 178 - 181
  • [26] Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
    Zamagni, Elena
    Tacchetti, Paola
    Pantani, Lucia
    Cavo, Michele
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (05) : 423 - 435
  • [27] Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
    De Novellis, Danilo
    Fontana, Raffaele
    Giudice, Valentina
    Serio, Bianca
    Selleri, Carmine
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
  • [28] Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects
    Horenstein, Alberto L.
    Faini, Angelo C.
    Morandi, Fabio
    Ortolan, Erika
    Storti, Paola
    Giuliani, Nicola
    Richardson, Paul G.
    Malavasi, Fabio
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [29] Effects of Soluble and MicrovesicleBound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
    Faini, Angelo Corso
    Castella, Barbara
    Horenstein, Alberto
    Morandi, Fabio
    Malavasi, Fabio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S418 - S418
  • [30] IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Kanellias, Nikolaos
    Eleutherakis-Papaiakovou, Evangelos
    Dialoupi, Ioanna
    Theodorakakou, Foteini
    Roussou, Maria
    Terpos, Evangelos
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    BLOOD, 2020, 136
12345